医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mannatech’s Ambrotose® Powders May Enhance Video Game Player Performance

2017年02月07日 AM09:30
このエントリーをはてなブックマークに追加


 

GUANGZHOU, China

Mannatech®, a global health and wellness company, believes that its Ambrotose supplement powders can support key performance factors for video gamers, including increased focus, attention and memory. Supporting these factors may have a positive, direct effect on player performance, which can be a big advantage for competitive e-sports players or those just trying to take down the bad guys in their favorite game.

According to clinical research at Mannatech, randomized, double-blind placebo-controlled human clinical trials published in peer reviewed journals have shown that Ambrotose powders can positively impact brainwaves associated with attention in young adults and improve memory and alertness in middle-aged adults.

“We have found in previous studies that Ambrotose powder may give a helpful boost in memory, focus and attention as well as having perceived beneficial changes in well-being,” said Dr. Rolando Maddela, MPH, CCRP, Mannatech’s Director of Clinical Research and Scientific Affairs. “For some involved in video games, Ambrotose products may give the competitive advantage they are looking for. For others it may make the video game playing experience simply more enjoyable. Just four grams per day of Advanced Ambrotose® in powder or capsules, taken according to directions, would be expected to support gamers’ performance.”

Mannatech’s Ambrotose powders are based on the company’s pioneering development of Glyconutritional technology. Glyconutritional technology encourages cellular communication and is shown to support cognitive functions – including memory, focus and attention, as well as supporting the body’s immune and digestive systems to encourage overall health.

Some of Mannatech’s core products are supported by industry-standard clinical studies including 17 human clinical trials that have been published, 12 of which were double-blind, placebo-controlled studies — the gold standard for product validation. For more on Mannatech’s rigorous scientific research, please visit MannatechScience.org.

From Mannatech’s e-commerce site^ in China, shoppers can now purchase Ambrotose products directly from the website and refer friends and family to shop. Please visit www.MeiTaiChina.com for details.

^Mannatech’s cross-border e-commerce model in China is a different opportunity from Mannatech’s MLM business in other markets. Our cross-border e-commerce model in China is not an MLM or direct selling business.

About Mannatech

Mannatech, Incorporated, offers a profound wellness experience that makes a difference in the lives of people across the world. Through its innovative Glyconutrition products, Mannatech changes lives, providing an unprecedented level of natural wellness, freedom and purpose. With more than 20 years of experience and operations in more than 26 markets, Mannatech is committed to transforming lives. For more information, visit MeiTaiChina.com.

Please note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005006/en/

CONTACT

Mannatech, Incorporated
Kalyn Dabbs, 972-471-7245
pr@mannatech.com

同じカテゴリーの記事 

  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表
  • The Office of Health Economics: Adult Vaccination Programmes Deliver Socio-economic Benefits up to 19 Times Initial Investment, According to New Report
  • Masimo创始人兼首席执行官Joe Kiani将在智利举行的全球患者安全峰会上谈论人工智能
  • マシモ創業者兼最高経営責任者(CEO)のジョー・キアニがチリで開催される世界患者安全サミットでAIについて講演
  • Codone Biotech to Present Data on its Suppressor-tRNA Platform in Disease Models with Nonsense Mutations (Premature Termination Codons)